

Announcement no. 14/2007

To OMX Nordic Exchange

Hørsholm, Denmark, 1 June 2007

LifeCycle Pharma A/S' total capital and the total number of voting rights

Hørsholm, Denmark, 1 June 2007; In accordance with section 17 (2) of the Danish Executive Order no. 226 of March 15, 2007 on the issuers' disclosure requirements, LifeCycle Pharma A/S (OMX:LCP) hereby informs that the total share capital of LifeCycle Pharma A/S amounts to DKK 30,514,048 consisting of 30,514,048 shares each of a nominal value of DKK 1. Each share of nominal value DKK 1 carries one voting right. Accordingly, the total number of voting rights is 30,514,048.

For further information please contact:

LifeCycle Pharma A/S

Michael Wolff Jensen

Executive Vice President and CFO

Tel. +45 40 74 62 44

---oo0oo---

About LifeCycle Pharma A/S:

LifeCycle Pharma, headquartered in Hørsholm, Denmark, is an emerging pharmaceutical company with a broad and late stage product pipeline in therapeutic areas of cholesterol management, hypertension, organ transplant and autoimmune diseases. LifeCycle Pharma's proprietary technology platform, MeltDose® technology, offers lower dosing, reduced side effects and improved safety and patient compliance, as well as reduced product development time and development costs. LifeCycle Pharma is listed on the OMX Nordic Exchange under the trading symbol (LCP). Please visit www.lcpharma.com for further information about LifeCycle Pharma A/S.